Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1155-1162

  Chorostowska Wynimko, Joanna ^a   Swiercz, Rafal ^b,c   Skrzypczak Jankun, Ewa ^b   Selman, Steven H ^b   Jankun, Jerzy ^b  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Endothelial cells; In vitro angiogenesis; Plasminogen activator inhibitor type 1; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; HALF LIFE TIME; HUMAN; LUNG; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); UMBILICAL VEIN; VASCULARIZATION;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HALF-LIFE; HUMANS; LUNG; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; UMBILICAL VEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 16644370193     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1155     Document Type: Article

References (50)

1. Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J: Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 13: 759-766, 2004.
2. Stefansson S and Lawrence DA: Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE: pe24, 2003.
3. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC and Lawrence DA: Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276: 8135-8141, 2001.
4. Zhou A, Huntington JA, Pannu NS, Carrell RW and Read RJ: How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544, 2003. (Pubitemid 36792905)
5. Palmieri D, Lee JW, Juliano RL and Church FC: Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 277: 40950-40957, 2002. (Pubitemid 35215683)
6. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000. (Pubitemid 30105328)
7. Czekay RP, Aertgeerts K, Curriden SA and Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160: 781-791, 2003. (Pubitemid 36298272)
8. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK and Barlovatz-Meimon G: Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 160: 237-246, 2002. (Pubitemid 34052284)
9. Gils A, Knockaert I and Declerck PJ: Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 35: 7474-7481, 1996. (Pubitemid 26189813)
10. Jankun J, Merrick HW and Goldblatt PJ: Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53: 135-144, 1993. (Pubitemid 23294599)
11. Jankun J: Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res 52: 5829-5832, 1992.
12. Jankun J, Maher VM and McCormick JJ: Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51: 1221-1226, 1991.
13. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2: 19-28, 2003.
14. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
15. Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH and Jankun J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep 6: 523-526, 1999.
16. Stefansson S, McMahon GA, Petitclerc E and Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9: 1545-1564, 2003. (Pubitemid 36763492)
17. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928, 1998. (Pubitemid 28364031)
18. Brodsky S, Chen J, Lee A, Akassoglou K, Norman J and Goligorsky MS: Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol 281: H1784-H1792, 2001.
19. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K and Johnsen M: Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 22: 4389-4397, 2003. (Pubitemid 36897969)
20. Eitzman DT, Krauss JC, Shen T, Cui J and Ginsburg: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722, 1996.
21. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM and Noel A: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784, 2001. (Pubitemid 34280162)
22. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA and Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60: 5839-5847, 2000.
23. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC and Lawrence DA: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968, 2001.
24. Lambert V, Munaut C, Carmeliet P, Gerard RD, Declerck PJ, Gils A, Claes C, Foidart JM, Noel A and Rakic JM: Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 44: 2791-2797, 2003. (Pubitemid 36618445)
25. Mayer EJ, Fujita T, Gardell SJ, Shebuski RJ and Reilly CF: The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. Blood 76: 1514-1520, 1990. (Pubitemid 20364014)
26. Levin EG and Santell L: Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 70: 1090-1098, 1987. (Pubitemid 18022388)
27. Lindahl TL, Sigurdardottir O and Wiman B: Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62: 748-751, 1989. (Pubitemid 19267430)
28. Ingber DE and Folkman J: How does extracellular matrix control capillary morphogenesis? Cell 58: 803-805, 1989. (Pubitemid 19227890)
29. Takahashi K, Uwabe Y, Sawasaki Y, Kiguchi T, Nakamura H, Kashiwabara K, Yagyu H and Matsuoka T: Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 275: L47-L54, 1998.
30. Muth H, Maus U, Wygrecka M, Lohmeyer J, Grimminger F, Seeger W and Gunther A: Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha. Crit Care Med 32: 217-226, 2004. (Pubitemid 38125584)
31. Barchowsky A, Roussel RR, Krieser RJ, Mossman BT and Treadwell MD: Expression and activity of urokinase and its receptor in endothelial and pulmonary epithelial cells exposed to asbestos. Toxicol Appl Pharmacol 152: 388-396, 1998. (Pubitemid 28492280)
32. Sidenius N and Blasi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222, 2003. (Pubitemid 36561058)
33. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM and Noel A: Role of plasminogen activator-plasmin system in tumor autogenesis. Cell Mol Life Sci 60: 463-473, 2003. (Pubitemid 36459526)
34. Dunbar SD, Ornstein DL and Zacharski LR: Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Expert Opin Investig Drugs 9: 2085-2092, 2000.
35. Kobayashi H, Suzuki M, Hiroshima Y and Terao T: The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 384: 749-754, 2003. (Pubitemid 36747936)
36. Kobayashi H: Suppression of urokinase expression and tumor metastasis by bikunin overexpression (mini-review). Hum Cell 14: 233-236, 2001.
37. Steimnetzer T: Synthetic urokinase inhibitors as potential antitumor drugs. IDrugs 6: 138-146, 2003.
38. Tacchini L, Matteucci E, De Ponti C and Desiderio MA: Hepatocyte growth factor signaling regulates transactivation of genes belongina to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 290: 391-401, 2003. (Pubitemid 37272181)
39. Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, Carmeliet P, Gabriele P and Bussolino F: Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res 63: 1500-1507, 2003. (Pubitemid 36373635)
40. Olson D, Pollanen J, Hoyer-Hansen G, Ronne E, Sakaguchi K, Wun TC, Appella E, Dano K and Blasi F: Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133, 1992.
41. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994. (Pubitemid 24138727)
42. Wilson MJ and Sinha AA: Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Cell Mol Biol Res 39: 751-760, 1993. (Pubitemid 24245315)
43. Mars WM, Zarnegar R and Michalopoulos GK: Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 143: 949-958, 1993. (Pubitemid 24058250)
44. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW and Lang SH: Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86: 1136-1142, 2002. (Pubitemid 34438087)
45. Billstrom A, Hartley-Asp B, Lecander I, Batra S and Astedt B: The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer 61: 542-547, 1995.
46. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ and Lehy T: Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 22: 1035-1042, 2001. (Pubitemid 32633601)
47. Koeneman KS, Yeung F and Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261, 1999. (Pubitemid 29244499)
48. Sparks RL, Pool TB, Smith NK and Cameron IL: Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Cancer Res 43: 73-77, 1983. (Pubitemid 13172797)
49. Jiang Y and Muschel RJ: Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res 62: 1910-1914, 2002. (Pubitemid 34408521)
50. Maragoudakis ME, Tsopanoglou NE and Andriopoulou P: Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 30: 173-177, 2002.